Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Prostate Cancer
Trial Locations (17)

V2S 3N5

Exdeo Clinical Research Inc., Abbotsford

V1Y 2H4

Southern Interior Medical Research Inc., Kelowna

V3V 1N1

Andreou Research, Surrey

V8V 3N1

Dr. Steinhoff Clinical Research, Victoria

L4M 7G1

The Male/Female Health and Research Centre, Barrie

L6T 4S5

Jonathan Giddens Medicine Professional Corporation, Brampton

N3R 4N3

Brantford Urology Research, Brantford

L7N 3V2

G. Kenneth Jansz Medicine Professional Corporation, Burlington

N1H 5J1

Guelph Urology Associates, Guelph

L3X 1W1

Mor Urology Inc., Newmarket

M6A 3B5

Toronto Urology Clinical Study Group, North York

L6H 3P1

The Fe/Male Health Centres, Oakville

N4K 2J1

2150935 Ontario Inc., Owen Sound

M1S 4V5

643094 Ontario Inc., Scarborough Village

M2J1V1

Stanley Flax Medical Professional Corporation, Toronto

J4V 2H3

Urology South Shore Research Inc., Greenfield Park

H7G 2E6

Urolaval, Laval

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

CMX Research

OTHER